Overview

A Pilot Bioequivalence Study of Pomalidomide

Status:
Completed

Trial end date:
2018-02-06

Target enrollment:

Participant gender:

Summary

Pomalidomide capsule were developed to offer an alternative to the marketed formulation, This pilot study was aim to pre-assess the bioequivalence of the capsule formulations under fasted condition.

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Collaborator:

Second Hospital of Shanxi Medical University

Treatments:

Pomalidomide
Thalidomide